Clinical Trial Update: Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting efficacy and safety results for Ultrase MT20 in improving the coefficient of fat absorption in children with cystic fibrosis and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis
• Pancreatic Insufficiency

Drugs mentioned

• ULTRASE MT20

Snippet

Sponsor: Forest Laboratories | Conditions: Cystic Fibrosis, Pancreatic Insufficiency | Phase 3 | Status: COMPLETED | Results posted: 2014-04-10